Alvotech SA has announced a new collaboration with Dr. Reddy's Laboratories Ltd. to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda® (pembrolizumab), a widely used cancer treatment. This partnership will leverage the strengths of both companies in biosimilar development, aiming to expedite the process and expand global access to this critical medication. Both companies will share responsibilities and costs associated with the development and manufacturing of the biosimilar. The agreement marks a significant step in providing cost-effective biologic treatments to patients worldwide, particularly in the field of oncology, which is a focus area for Dr. Reddy's. Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.